{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:26:42Z","timestamp":1794565602976,"version":"4.9.1"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["ID 101094131"],"award-info":[{"award-number":["ID 101094131"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118997","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:23:36Z","timestamp":1779319416000},"page":"118997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["From fragments to drugs: How AI and in silico methods accelerate fragment-to-lead optimization"],"prefix":"10.1016","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4837-7849","authenticated-orcid":false,"given":"Elnaz","family":"Aledavood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8307-5670","authenticated-orcid":false,"given":"Jannis","family":"Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-6081","authenticated-orcid":false,"given":"Carmen","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118997_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nchem.217","article-title":"The rise of fragment-based drug discovery","volume":"1","author":"Murray","year":"2009","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115301","article-title":"Recent trends in fragment-based anticancer drug design strategies against different targets: a mini-review","volume":"206","author":"Moinul","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118997_bib3","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/1878-0261.13277","article-title":"Fragment-based drug Discovery\u2014The importance of high-quality molecule libraries","volume":"16","author":"Bon","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118997_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-Mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118997_bib13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a novel small molecule csf-1r inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.118997_bib14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/DDDT.S109325","article-title":"Development of venetoclax for therapy of lymphoid malignancies","volume":"11","author":"Zhu","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.118997_bib15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery & pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118997_bib16","doi-asserted-by":"crossref","first-page":"12453","DOI":"10.1021\/acs.jmedchem.1c00511","article-title":"Berotralstat (BCX7353): structure-guided design of a potent, selective, and oral plasma kallikrein inhibitor to prevent attacks of hereditary angioedema (HAE)","volume":"64","author":"Kotian","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib18","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib19","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1021\/jm301762v","article-title":"Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of akt kinases","volume":"56","author":"Addie","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib4","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1021\/acs.jmedchem.5c00424","article-title":"Fragment-based drug design: from then until now, and toward the future","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400342","article-title":"How to find a fragment: methods for screening and validation in fragment-based drug discovery","volume":"19","author":"Kirkman","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118997_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrd3926-c1","article-title":"The \u201crule of three\u201d for fragment-based drug discovery: where are we now?","volume":"12","author":"Jhoti","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118997_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2026.118997_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108197","article-title":"Fragment-based drug discovery: small fragments, big impact \u2212 success stories of approved oncology therapeutics","volume":"156","author":"Khedkar","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrd.2016.109","article-title":"Twenty years on: the impact of fragments on drug discovery","volume":"15","author":"Erlanson","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118997_bib10","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/molecules24234309","article-title":"Concepts and core principles of fragment-based drug design","volume":"24","author":"Kirsch","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118997_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/17460441.2019.1583643","article-title":"A bright future for fragment-based drug discovery: what does it hold?","volume":"14","author":"Jacquemard","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118997_bib20","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1021\/acs.jmedchem.6b00197","article-title":"Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia","volume":"59","author":"Keseru","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib21","first-page":"321","article-title":"Fragment-based drug discovery: opportunities for organic synthesis, RSC med","volume":"12","author":"Denis","year":"2021","journal-title":"Chem"},{"key":"10.1016\/j.ejmech.2026.118997_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1039\/D1MD00363A","article-title":"Comprehensive analysis of commercial fragment libraries","volume":"13","author":"Revillo Imbernon","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib23","unstructured":"Life Chemicals Fragment Library, lifechemicals.com\/fragment-libraries\/soluble-fragment-library\/(accessed January 12, 2026)."},{"key":"10.1016\/j.ejmech.2026.118997_bib24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1039\/D0CB00222D","article-title":"Fragment-based covalent ligand discovery","volume":"2","author":"Lu","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118997_bib25","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.drudis.2022.05.021","article-title":"Escape from planarity in fragment-based drug discovery: a synthetic strategy analysis of synthetic 3D fragment libraries","volume":"27","author":"Klein","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118997_bib26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1021\/acs.jcim.2c01253","article-title":"ZINC-22\u2500A free multi-billion-scale database of tangible compounds for ligand discovery","volume":"63","author":"Tingle","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib27","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1039\/C5SC03115J","article-title":"A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain","volume":"7","author":"Cox","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1107\/S2052520616003954","article-title":"The Cambridge structural database","volume":"72","author":"Groom","year":"2016","journal-title":"Acta Crystallogr. B Struct. Sci. Cryst. Eng. Mater."},{"key":"10.1016\/j.ejmech.2026.118997_bib29","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acschembio.8b00389","article-title":"Isolation of gracilins H (5), I (6), and A (7) from spongionella sp","volume":"13","author":"Thornburg","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118997_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10822-024-00551-7","article-title":"SpaceGrow: efficient shape-based virtual screening of billion-sized combinatorial fragment spaces","volume":"38","author":"H\u00f6nig","year":"2024","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2026.118997_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/acs.jcim.7b00020","article-title":"Fragment database FDB-17","volume":"57","author":"Visini","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib32","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1021\/acs.jcim.8b00285","article-title":"PADFrag: a database built for the exploration of bioactive fragment space for drug discovery","volume":"58","author":"Yang","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/acs.jcim.6b00596","article-title":"Break Down in order to build up: decomposing small molecules for fragment-based drug design with eMolFrag","volume":"57","author":"Liu","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42004-024-01346-5","article-title":"DigFrag as a digital fragmentation method used for artificial intelligence-based drug design","volume":"7","author":"Yang","year":"2024","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170131","article-title":"Critical features of fragment libraries for protein structure prediction","volume":"12","author":"Trevizani","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118997_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2025.100233","article-title":"Fragment-based drug discovery: a graphical review","volume":"9","author":"AlKharboush","year":"2025","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118997_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/2472555220916168","article-title":"Applied biophysical methods in fragment-based drug discovery","volume":"25","author":"Coyle","year":"2020","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.ejmech.2026.118997_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00723-019-01182-0","article-title":"13C saturation-transfer difference (STD)-NMR experiments using INEPT polarization transfer","volume":"51","author":"Xu","year":"2020","journal-title":"Appl. Magn. Reson."},{"key":"10.1016\/j.ejmech.2026.118997_bib46","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1080\/14756366.2019.1636235","article-title":"1D NMR WaterLOGSY as an efficient method for fragment-based lead discovery","volume":"34","author":"Raingeval","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib47","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/molecules21070860","article-title":"Applications of 19F-NMR in fragment-based drug discovery","volume":"21","author":"Norton","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118997_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116114","article-title":"An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer","volume":"265","author":"Myers","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.mrl.2021.100025","article-title":"Recent progress in fragment-based drug discovery facilitated by NMR spectroscopy","volume":"2","author":"Wang","year":"2022","journal-title":"Magn. Reson. Lett."},{"key":"10.1016\/j.ejmech.2026.118997_bib50","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1021\/acs.analchem.3c01362","article-title":"Application of 15N-Edited 1H-13C correlation NMR spectroscopy\u2500toward fragment-based metabolite identification and screening via HCN constructs","volume":"95","author":"Lysak","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib51","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/molecules26030576","article-title":"Applications of solution nmr in drug discovery","volume":"26","author":"Shi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118997_bib52","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1021\/acs.jmedchem.9b00134","article-title":"Structure-guided discovery of a selective mcl-1 inhibitor with cellular activity","volume":"62","author":"Szl\u00e1vik","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib53","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.drudis.2019.03.009","article-title":"Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design","volume":"24","author":"O'Reilly","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118997_bib54","article-title":"Achieving efficient fragment screening at XChem facility at diamond light source","volume":"171","author":"Douangamath","year":"2021","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejmech.2026.118997_bib55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1107\/S2059798322000705","article-title":"Fast fragment- and compound-screening pipeline at the Swiss light source","volume":"78","author":"Kaminski","year":"2022","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.118997_bib56","first-page":"235","article-title":"Fast fragment and compound screening pipeline at the Swiss light source","volume":"vol. 690","author":"Stegmann","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118997_bib57","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1107\/S205979832000889X","article-title":"FragMAX: the fragment-screening platform at the MAX IV laboratory","volume":"76","author":"Lima","year":"2020","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.118997_bib58","doi-asserted-by":"crossref","first-page":"12857","DOI":"10.3390\/ijms131012857","article-title":"Fragment-based screening by protein crystallography: successes and pitfalls","volume":"13","author":"Chilingaryan","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib59","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2212931120","article-title":"Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2","volume":"120","author":"Gahbauer","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.118997_bib60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10408347.2014.881250","article-title":"Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis","volume":"45","author":"Olaru","year":"2015","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib61","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/adt.2011.0380","article-title":"Molecular interaction studies using microscale thermophoresis","volume":"9","author":"Jerabek-Willemsen","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejmech.2026.118997_bib62","series-title":"Protein-Ligand Interactions Methods and Applications","author":"Williams","year":"2013"},{"key":"10.1016\/j.ejmech.2026.118997_bib63","doi-asserted-by":"crossref","first-page":"12984","DOI":"10.1073\/pnas.1304045110","article-title":"Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery","volume":"110","author":"Silvestre","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.118997_bib64","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.drudis.2019.12.006","article-title":"Fragment-based drug discovery using cryo-EM","volume":"25","author":"Saur","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118997_bib65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fchem.2020.00093","article-title":"In silico strategies to support fragment-to-lead optimization in drug discovery","volume":"8","author":"de Souza Neto","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib66","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/cbdd.14120","article-title":"Development of potent inhibitors by fragment-linking strategies","volume":"100","author":"Bedwell","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2026.118997_bib67","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.1021\/acs.jmedchem.3c01009","article-title":"FFLOM: a flow-based autoregressive model for fragment-to-lead optimization","volume":"66","author":"Jin","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib99","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/acs.jmedchem.7b01558","article-title":"Binding-site compatible fragment growing applied to the design of \u03b2 2 -Adrenergic receptor ligands","volume":"61","author":"Chevillard","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib73","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1021\/acs.jmedchem.8b00653","article-title":"Integrated strategy for lead optimization based on fragment growing: the diversity-oriented-target-focused-synthesis approach","volume":"61","author":"Hoffer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/acscentsci.7b00401","article-title":"Chemical space expansion of bromodomain ligands guided by in silico virtual couplings (AutoCouple)","volume":"4","author":"Batiste","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib101","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ejmech.2018.11.075","article-title":"NAOMInext \u2013 synthetically feasible fragment growing in a structure-based design context","volume":"163","author":"Sommer","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib102","doi-asserted-by":"crossref","first-page":"W25","DOI":"10.1093\/nar\/gkad348","article-title":"Acfis 2.0: an improved web-server for fragment-based drug discovery via a dynamic screening strategy","volume":"51","author":"Shi","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118997_bib103","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1039\/D1SC00163A","article-title":"DeepFrag: a deep convolutional neural network for fragment-based lead optimization","volume":"12","author":"Green","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib104","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13321-020-00431-w","article-title":"CReM: chemically reasonable mutations framework for structure generation","volume":"12","author":"Polishchuk","year":"2020","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2026.118997_bib105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13321-020-00429-4","article-title":"AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization","volume":"12","author":"Spiegel","year":"2020","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2026.118997_bib95","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1021\/acs.jcim.9b01120","article-title":"Deep generative models for 3D linker design","volume":"60","author":"Imrie","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib106","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1021\/acs.jcim.1c00630","article-title":"Efficient hit-to-lead searching of kinase inhibitor chemical space via computational fragment merging","volume":"61","author":"Andrianov","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib107","series-title":"Schrodinger, Schrodinger Release 2025-4","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118997_bib98","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1039\/D0SC03126G","article-title":"SyntaLinker: automatic fragment linking with deep conditional transformer neural networks","volume":"11","author":"Yang","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13321-025-00946-0","article-title":"Fragmenstein: predicting protein\u2013ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding\u2013based methodology","volume":"17","author":"Ferla","year":"2025","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2026.118997_bib108","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1021\/jm030543u","article-title":"BREED: generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease","volume":"47","author":"Pierce","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib109","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1021\/acs.jcim.9b00699","article-title":"Fragment-based computational method for designing GPCR ligands","volume":"60","author":"Li","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib68","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/minf.201000174","article-title":"Compound design by fragment-linking","volume":"30","author":"Ichihara","year":"2011","journal-title":"Mol. Inf."},{"key":"10.1016\/j.ejmech.2026.118997_bib69","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.bmc.2017.04.037","article-title":"A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066","volume":"25","author":"De Fusco","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib70","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.tips.2015.08.003","article-title":"Lessons from hot spot analysis for fragment-based drug discovery","volume":"36","author":"Hall","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0959-440X(02)00283-X","article-title":"Unraveling hot spots in binding interfaces: progress and challenges","volume":"12","author":"DeLano","year":"2002","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.118997_bib72","doi-asserted-by":"crossref","first-page":"11420","DOI":"10.1021\/acs.jmedchem.0c00242","article-title":"Fragment linking strategies for structure-based drug design","volume":"63","author":"Bancet","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib74","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.201900296","article-title":"Fragment growing to design optimized inhibitors for human blood group B galactosyltransferase (GTB)","volume":"14","author":"Strecker","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118997_bib75","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1021\/acs.jcim.3c00276","article-title":"Fragment merging using a graph database samples different catalogue space than similarity search","volume":"63","author":"Wills","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib76","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bmcl.2016.08.016","article-title":"Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol","volume":"27","author":"Xu","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118997_bib77","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.bmc.2019.02.006","article-title":"Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy","volume":"27","author":"Miyake","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2025.102995","article-title":"From part to whole: AI-Driven progress in fragment-based drug discovery","volume":"91","author":"Yoo","year":"2025","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.118997_bib79","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1021\/acs.jcim.0c01160","article-title":"FRAGSITE: a fragment-based approach for virtual ligand screening","volume":"61","author":"Zhou","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib80","first-page":"674","article-title":"Chemical representation learning for toxicity prediction","volume":"2","author":"Born","year":"2023","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejmech.2026.118997_bib81","article-title":"Uni-mol: a universal 3D molecular representation learning framework","author":"Zhou","year":"2023","journal-title":"ICLR"},{"key":"10.1016\/j.ejmech.2026.118997_bib82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118997_bib83","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.adl2528","article-title":"Generalized biomolecular modeling and design with RoseTTAFold all-atom","volume":"384","author":"Krishna","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118997_bib84","article-title":"Boltz-2: towards accurate and efficient binding affinity prediction","author":"Passaro","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.118997_bib85","series-title":"MLSB Workshop","article-title":"DiffDock: diffusion steps, twists, and turns for molecular docking","author":"Corso","year":"2022"},{"key":"10.1016\/j.ejmech.2026.118997_bib86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13321-021-00522-2","article-title":"Gnina 1.0: molecular docking with deep learning","volume":"13","author":"McNutt","year":"2021","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2026.118997_bib87","article-title":"EQUIBIND: geometric deep learning for drug binding structure prediction","author":"St\u00e4rk","year":"2022","journal-title":"ICML"},{"key":"10.1016\/j.ejmech.2026.118997_bib88","article-title":"Learning to extend molecular scaffolds with structural motifs","author":"Maziarz","year":"2022","journal-title":"ICLR"},{"key":"10.1016\/j.ejmech.2026.118997_bib89","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s42256-023-00639-z","article-title":"Regression transformer enables concurrent sequence regression and generation for molecular language modelling","volume":"5","author":"Born","year":"2023","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.ejmech.2026.118997_bib90","article-title":"Toward fully autonomous closed-loop molecular discovery \u2013 a case study on JAK targets","author":"Born","year":"2026","journal-title":"Chem"},{"key":"10.1016\/j.ejmech.2026.118997_bib92","series-title":"Flow Network Based Generative Models for Non-iterative Diverse Candidate Generation","author":"Bengio","year":"2021"},{"key":"10.1016\/j.ejmech.2026.118997_bib93","article-title":"SynFlowNet: design of diverse and novel molecules with synthesis constraints","author":"Cretu","year":"2025","journal-title":"ICLR"},{"key":"10.1016\/j.ejmech.2026.118997_bib94","doi-asserted-by":"crossref","first-page":"19452","DOI":"10.1039\/D4SC04620J","article-title":"FragGen: towards 3D geometry reliable fragment-based molecular generation","volume":"15","author":"Zhang","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib96","doi-asserted-by":"crossref","first-page":"14577","DOI":"10.1039\/D1SC02436A","article-title":"Deep generative design with 3D pharmacophoric constraints","volume":"12","author":"Imrie","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib97","first-page":"392","article-title":"Link-INVENT: generative linker design with reinforcement learning","volume":"2","author":"Guo","year":"2023","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejmech.2026.118997_bib110","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/med.21255","article-title":"Fragment informatics and computational fragment-based drug design: an overview and update","volume":"33","author":"Sheng","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118997_bib111","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.drudis.2020.06.023","article-title":"The rise of molecular simulations in fragment-based drug design (FBDD): an overview","volume":"25","author":"Bissaro","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118997_bib112","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/acs.jcim.5b00538","article-title":"Accurate binding free energy predictions in fragment optimization","volume":"55","author":"Steinbrecher","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib113","article-title":"Integrative computational approaches for discovery and evaluation of lead compound for drug design, front","volume":"4","author":"Naithani","year":"2024","journal-title":"Drug Discov"},{"key":"10.1016\/j.ejmech.2026.118997_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075992","article-title":"Ligand pose and orientational sampling in molecular docking","volume":"8","author":"Coleman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118997_bib115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ejmech.2018.07.042","article-title":"In silico fragment-based drug design with SEED","volume":"156","author":"Marchand","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib116","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1021\/acs.jmedchem.6b01437","article-title":"Recent advances in scaffold hopping","volume":"60","author":"Hu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib117","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1021\/acs.jcim.5c00029","article-title":"Scaffold hopping with generative reinforcement learning","volume":"65","author":"Rossen","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.657222","article-title":"Perspectives on high-throughput ligand\/protein docking with martini MD simulations","volume":"8","author":"Souza","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2026.118997_bib119","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/acs.accounts.9b00613","article-title":"Investigating cryptic binding sites by molecular dynamics simulations","volume":"53","author":"Kuzmanic","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118997_bib120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1021\/acsmedchemlett.2c00541","article-title":"Recent advances in alchemical binding free energy calculations for drug discovery","volume":"14","author":"Muegge","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118997_bib121","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/ci700424b","article-title":"Fragment-based de Novo Ligand design by multiobjective evolutionary optimization","volume":"48","author":"Dey","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib122","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10822-006-9099-2","article-title":"Structure and reaction based evaluation of synthetic accessibility","volume":"21","author":"Boda","year":"2007","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2026.118997_bib123","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1021\/acs.jcim.3c01134","article-title":"DFRscore: deep learning-based scoring of synthetic complexity with drug-focused retrosynthetic analysis for high-throughput virtual screening","volume":"64","author":"Kim","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118997_bib124","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13321-020-00439-2","article-title":"SYBA: bayesian estimation of synthetic accessibility of organic compounds","volume":"12","author":"Vor\u0161il\u00e1k","year":"2020","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2026.118997_bib125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13321-020-00472-1","article-title":"AiZynthFinder: a fast, robust and flexible open-source software for retrosynthetic planning","volume":"12","author":"Genheden","year":"2020","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2026.118997_bib126","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1021\/acs.accounts.5c00155","article-title":"ASKCOS: open-source, data-driven synthesis planning","volume":"58","author":"Tu","year":"2025","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118997_bib127","series-title":"Lessons learned from multi-year operation of a cloud-hosted commercial robot driven by domain-specific language models","author":"Manica","year":"2026"},{"key":"10.1016\/j.ejmech.2026.118997_bib128","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1021\/acscentsci.9b00576","article-title":"Molecular transformer: a model for uncertainty-calibrated chemical reaction prediction","volume":"5","author":"Schwaller","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib129","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1039\/C9SC05704H","article-title":"Predicting retrosynthetic pathways using transformer-based models and a hyper-graph exploration strategy","volume":"11","author":"Schwaller","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41524-024-01290-x","article-title":"Growing strings in a chemical reaction space for searching retrosynthesis pathways","volume":"10","author":"Zipoli","year":"2024","journal-title":"npj Comput. Mater."},{"key":"10.1016\/j.ejmech.2026.118997_bib131","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1021\/acs.chemrev.4c00055","article-title":"Self-driving laboratories for chemistry and materials science","volume":"124","author":"Tom","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118997_bib132","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118997_bib133","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0014-2013","article-title":"Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis : genes, mutations, and causalities","volume":"2","author":"Vilch\u00e8ze","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2026.118997_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115569","article-title":"Recent advances in Fragment-based strategies against tuberculosis","volume":"258","author":"Villemagne","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib135","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1021\/acs.jmedchem.0c00007","article-title":"Fragment-based design of Mycobacterium tuberculosis inha inhibitors","volume":"63","author":"Sabbah","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib136","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118997_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105344","article-title":"Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening","volume":"203","author":"Roy","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.118997_bib138","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf8711","article-title":"Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking","volume":"7","author":"Schuller","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118997_bib139","doi-asserted-by":"crossref","first-page":"RP103484","DOI":"10.7554\/eLife.103484.3","article-title":"The Mac1 ADP-Ribosylhydrolase is a therapeutic target for SARS-CoV-2","volume":"14","author":"Suryawanshi","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118997_bib140","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging all KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118997_bib141","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","article-title":"Drugging KRAS: current perspectives and state-of-art review","volume":"15","author":"Parikh","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118997_bib142","doi-asserted-by":"crossref","first-page":"14614","DOI":"10.1021\/acs.jmedchem.2c01120","article-title":"Fragment optimization of reversible binding to the switch II pocket on KRAS leads to a potent, in vivo active KRASG12CInhibitor","volume":"65","author":"Br\u00f6ker","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118997_bib143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1021\/acs.chemrev.6b00177","article-title":"GPCR dynamics: structures in motion","volume":"117","author":"Latorraca","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118997_bib144","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118997_bib145","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.tibs.2023.01.008","article-title":"Fragment-based drug discovery supports drugging \u2018undruggable\u2019 protein\u2013protein interactions","volume":"48","author":"Wang","year":"2023","journal-title":"Trends Biochem. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:01:25Z","timestamp":1794564085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":138,"alternative-id":["S0223523426004423"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118997","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From fragments to drugs: How AI and in silico methods accelerate fragment-to-lead optimization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118997"}}